Strata Oncology, Ann Arbor, Mich, has launched StrataNGS 3.0, an updated version of the company’s pan-cancer assay for solid tumors. The updated 500-gene assay utilizes DNA and RNA from tumor samples to detect all clinically actionable biomarkers recommended by leading guidelines—including microsatellite instability, tumor mutational burden, and PD-L1—in a single test. Test results are provided in a streamlined report that facilitates rapid, confident interpretation and identification of potential treatment options and clinical trials.
“Our expanded assay, providing deep cancer insights and leading performance, represents our commitment to bring a best-in-class diagnostic to oncologists and pathologists across the Strata network of health systems,” says Scott Tomlins, MD, PhD, chief medical officer of Strata Oncology. “In addition to providing physicians with all relevant genomic information needed to make an informed treatment decision, the test will help inform new trial design and accelerate drug development.”
StrataNGS is provided at no cost to advanced cancer patients enrolled in the Strata trial at the company’s partner health systems. The test requires low sample input, and returns results in less than 10 business days. It employs RNA sequencing and DNA sequencing to simultaneously detect mutations, small frame-preserving insertions and deletions (indels), amplifications, deep deletions, de novo deleterious mutations, gene fusion events, microsatellite instability, tumor mutational burden, and PD-L1.
In addition, the updated assay includes analytical validation of 36 gene expression markers that represent emerging immunooncology and antibody-drug conjugate targets. Although such biomarkers are not yet reported clinically, the data are available to Strata Oncology and investigators at partner cancer centers for correlative analyses and new trial design.
For further information, visit Strata Oncology.
Featured image: StrataNGS; photo courtesy Strata Oncology.